Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).
Authors
Ho Yeong Lim
Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea
Ho Yeong Lim , Jeong Heo , Tae-You Kim , Wai Meng David Tai , Yoon-Koo Kang , George Lau , Masatoshi Kudo , Won Young Tak , Magdalena Watras , Sajid K Ali , Alejandra Negro , Ghassan K. Abou-Alfa , Robin Kate Kelley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02519348
DOI
10.1200/JCO.2022.40.4_suppl.436
Abstract #
436
Poster Bd #
C3
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
First Author: Eileen Mary O'Reilly
Poster
2017 ASCO Annual Meeting
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
First Author: Robin Kate Kelley
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).
First Author: Ghassan K. Abou-Alfa
Poster
2024 ASCO Annual Meeting
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa